SUMMARY Two independent lines of chemically-induced colonic carcinoma, serially graftable in syngeneic rats, have been used to investigate the effects of immunoprophylaxis and immunotherapy. Rats were immunised by various procedures, including BCG, irradiated tumour grafts, and cancer cells treated by mitomycin and neuraminidase. A partial inhibition of tumour growth was observed in one of the four tested protocols. On the other hand, a significant enhancement of tumour growth was obtained in two other experiments.
Patients with colon carcinoma have been shown to react immunologically against tumour-associated antigens (Hellstrom et al., 1970; Hollinshead et al., 1970; . This finding suggests the use of immunotherapy to secure the surgical cure of this tumour. Demonstration of the objective effects of immunotherapy and the choice of the most efficient method require prolonged study in humans, because of the slow evolution of colorectal cancer. For this reason, we have chosen an animal model of chemically-induced colonic cancer (Martin et al., 1973a) . The following report deals with our preliminary attempts to treat rat colonic cancer by specific or non-specific immunological treatment.
Methods

ANIMALS
All rats were of the inbred BD-IX strain, maintained by continuous brother-sister mating. Inbreeding has been confirmed by permanent acceptance of skin grafts.
TUMOURS
Two serially graftable tumour lines, DHB and DHD, were independently obtained from colonic adenocarcinomas induced by 1,2 dimethylhydrazine (Martin et al., 1973b (Martin et al., 1975) .
CHALLENGING CELLS
They were obtained either by 0-25 % trypsinisation of established cell cultures (experiments 1, 2, and 3), or by dissociation of freshly removed tumour grafts, using 0-25 % pronase and 0'005 % desoxyribonuclease, according to Bartlett and Zbar (1972) was 0 4 g in controls and 3-1 g in treated animals (p< 0-01).
EXPERIMENT 2
Another group of eight rats received three intraperitoneal injections at two week intervals of 2 x 106, 4 x 106, and 2 x 106 DHD cells treated by mitomycin and neuraminidase. Two weeks after the last injection, this group and paired controls were injected subcutaneously with 106 untreated DHD cells. They were killed 50 days later. The tumour incidence was the same (five out of eight) in both groups. The mean tumour weight was 244 mg in the control group and 820 mg in the treated group (not significant). EXPERIMENT 3 Two groups of 10 rats were challenged by subcutaneous injection of 106 viable DHD cells. Ten days later, one group received a series of six subcutaneous injections (every other day) of 2 5 mg BCG mixed with 106 mitomycin-and neuraminidasetreated DHD cells. Animals of both groups were killed 122 days after the challenge. Tumours were found in seven out of 10 controls and all the 10 treated animals (riot significant). The mean tumour weight was 1 6 g in controls and 10-9 g in immunised rats (p < 0-01). Lung metastases occurred in one control and eight treated rats (p = 0-005). EXPERIMENT 4 Seven groups of eight rats were challenged on the same day by subcutaneous injection of 106 viable DHD cells obtained by enzymatic dissociation of freshly removed tumour grafts. One group received no other treatment (control group). The six other groups were inoculated with 9 5 mg BCG in 0-5 ml phosphate buffered saline at different times before or after challenge. BCG was always injected at the exact challenge site or into the tumour when a cancer nodule was detectable. The local inflammatory reaction induced by BCG was usually mild, limited to a small subcutaneous nodule, disappearing 15 to 25 days after BCG inoculation. Group I received BCG seven days before challenge. In group II, BCG was inoculated together with the tumour cells. In group III, IV, V, and VI, BCG was given respectively five, 10, 15, and 20 days after challenge. Tumour grew in all control animals with palpable growth being observed between 10 and 15 days after inoculation. All the rats were killed on the 56th day after the challenge. Results of the experiment are summarised in the Table. The number of tumour-free animals was not significantly different from the control group except for group II (BCG given together with the tumour cells), in which six out of eight rats were tumour-free at the end of the experiment. The mean tumour weight was smaller in the rats receiving BCG after tumour cells injection; the difference was significant for group V (BCG inoculated 15 days after challenge).
Discussion
In the four reported experiments, the effect of immunological treatment on the growth of grafted colonic tumours was rather disappointing. The one favourable effect was obtained in experiment 4, where BCG alone was used as immunostimulating agent. In this experiment, tumour growth was slower when BCG was injected into an established tumour and was often suppressed when BCG was inoculated together with the challenging cells. Suppression of tumour growth by the injection of tumour cells admixed with BCG has previously been reported by Baldwin and Pim (1973) and Kreider et al. (1976) ; unfortunately, this suppressive effect has no clinical equivalence.
On the other hand, significant enhancement of tumour growth was demonstrated in experiments 1 and 3, where tumour cells, or tumour cells plus BCG, were used for immunostimulatory therapy. This enhancement was surprisingly great as the tumours were approximately seven times larger in treated animals than in controls. The increased incidence of lung metastases observed in experiment 3 was also highly significant.
The factor responsible for tumour enhancement could not be defined. Serial immunisation with irradiated (15,000 r) tumour grafts, which gives enhancement in our experiment 1, was successfully used by Baldwin and Barker (1967) to prevent growth of rat hepatoma. Simmons and Rios (1973) were able to cure 24 out of 42 fibrosarcomas established in mice by repeated injections of BCG plus mitomycine-and neuraminidase-treated tumour cells; their protocol was very similar to that used in our experiment 3. Enhancement of tumour growth by BCG and/or neuraminidase treated cells has previously been reported (Piessens et al., 1970; Baldwin and Pim, 1973; Sparks and Breeding, 1974) , although the conditions leading to protection or enhancement have never been clearly determined. It has been suggested that the effectiveness of BCGinduced suppression of tumours depends on the immunogenicity of the target tumour (Baldwin and Pim, 1973 . Steele and Sjogren (1974) demonstrated that various rat colonic carcinomas shared a surface antigen inducing lymphocyte-mediated cytotoxicity. However, the effect of this antigen in tumour prevention could be inhibited by circulating blocking factors (Steele et al., 1975) .
It is also possible that rat colonic carcinoma is particularly susceptible to immunological enhancement. This hypothesis agrees with data from Rogers and Gildin (1975) on the effects of BCG treatment on dimethylhydrazine-induced rat colon cancer: BCG injected into the intestinal wall did not significantly alter the incidence of colonic carcinomas, but increased the percentage of animals with metastases.
Even if results obtained in animal models must be extrapolated with caution, present data emphasise the potential hazards of tumour enhancement in the immunotherapy of human colorectal cancer. At the present time, a few trials of immunotherapy of human intestinal cancer have been reported (Moertel et al., 1975; Falk et al., 1976; Mavligit et al., 1976 ). They were not conclusive, mainly because the patients were not randomised before being entered in the trial. Additional experimental studies, using different immunisation procedures, could help the clinician to define the factors leading to suppression, instead of enhancement, of human colorectal cancer growth.
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